Snir Olivia L, Buza Natalia, Hui Pei
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Histopathology. 2016 Sep;69(3):383-92. doi: 10.1111/his.12959. Epub 2016 Apr 12.
The association of ovarian mucinous tumours with teratomas is well documented at tissue level, suggesting that some ovarian mucinous tumours arise from teratomas. Teratomas, being of germ cell origin, are genetically distinct from somatic cells, therefore providing a molecular basis for DNA genotyping to separate teratoma-derived mucinous tumours from metastatic ones. We assessed the diagnostic utility of DNA genotyping in ovarian mucinous tumours.
Nine cases of ovarian mucinous borderline tumours and three mucinous carcinomas associated with teratomas were included, along with three mucinous tumours without associated teratoma for genotyping control. Target tissues (teratoma, mucinous tumour and paired normal tissue) were dissected microscopically, followed by genotyping at 15 short tandem repeat polymorphic loci. Of the 12 mucinous tumours with associated teratoma, tissue genotyping was informative in six cases, including four borderline tumours and two mucinous carcinomas. Homozygosity or partial homozygosity was observed in the teratomatous component in all six cases. Genotypical concordance between the teratoma and mucinous tumour was seen in five cases, including three borderline tumours and two mucinous carcinomas, suggesting clonal evolution. One mucinous borderline tumour showed an unmatched genotype with that of the corresponding teratoma, consistent with disparate tumour origins. All three mucinous tumours without teratoma displayed heterozygosity.
When associated with a teratoma, ovarian mucinous tumours may arise frequently from the coexisting teratoma. In difficult cases, DNA genotyping may be used as a diagnostic tool in separating teratoma-derived primary ovarian mucinous tumours from those of somatic origin, particularly metastatic tumours from other sites.
卵巢黏液性肿瘤与畸胎瘤在组织学水平的关联已有充分记录,提示部分卵巢黏液性肿瘤起源于畸胎瘤。畸胎瘤起源于生殖细胞,在基因上与体细胞不同,因此为DNA基因分型提供了分子基础,以区分畸胎瘤来源的黏液性肿瘤和转移性黏液性肿瘤。我们评估了DNA基因分型在卵巢黏液性肿瘤中的诊断效用。
纳入9例卵巢黏液性交界性肿瘤和3例与畸胎瘤相关的黏液性癌,以及3例无相关畸胎瘤的黏液性肿瘤作为基因分型对照。在显微镜下解剖目标组织(畸胎瘤、黏液性肿瘤和配对的正常组织),然后在15个短串联重复多态性位点进行基因分型。在12例与畸胎瘤相关的黏液性肿瘤中,6例组织基因分型结果可提供信息,包括4例交界性肿瘤和2例黏液性癌。所有6例中,在畸胎瘤成分中均观察到纯合性或部分纯合性。5例中可见畸胎瘤与黏液性肿瘤之间的基因型一致性,包括3例交界性肿瘤和2例黏液性癌,提示克隆进化。1例黏液性交界性肿瘤显示与相应畸胎瘤基因型不匹配,与不同的肿瘤起源一致。所有3例无畸胎瘤的黏液性肿瘤均表现为杂合性。
当与畸胎瘤相关时,卵巢黏液性肿瘤可能常起源于共存的畸胎瘤。在疑难病例中,DNA基因分型可作为一种诊断工具,用于区分畸胎瘤来源的原发性卵巢黏液性肿瘤和体细胞来源的肿瘤,特别是来自其他部位的转移性肿瘤。